Synapse

← Clinical Pharmacology Advances and Applications

Papers in Clinical Pharmacology Advances and Applications

Page 4 · newest first

  1. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxabanSHILAP Revista de lepidopterología · 2014
  2. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage formsClinical Pharmacology Advances and Applications · 2014
  3. Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawalClinical Pharmacology Advances and Applications · 2014
  4. Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction studyClinical Pharmacology Advances and Applications · 2014
  5. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogensClinical Pharmacology Advances and Applications · 2014
  6. Reducing medication errors in critical care: a multimodal approachClinical Pharmacology Advances and Applications · 2014
  7. Melatonergic drugs in developmentClinical Pharmacology Advances and Applications · 2014
  8. Effect of age and sex on warfarin dosingClinical Pharmacology Advances and Applications · 2014
  9. Differential renal adverse effects of ibuprofen and indomethacin in preterm infants: a reviewClinical Pharmacology Advances and Applications · 2014
  10. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetesClinical Pharmacology Advances and Applications · 2014
  11. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibClinical Pharmacology Advances and Applications · 2014
  12. Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation studyClinical Pharmacology Advances and Applications · 2014
  13. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteersClinical Pharmacology Advances and Applications · 2014
  14. Population pharmacokinetics of olprinone in healthy male volunteersClinical Pharmacology Advances and Applications · 2014
  15. The clinical potential of influencing Nrf2 signaling in degenerative and immunological disordersClinical Pharmacology Advances and Applications · 2014
  16. Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysClinical Pharmacology Advances and Applications · 2014
  17. Chronic hepatitis C: future treatmentClinical Pharmacology Advances and Applications · 2014
  18. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel responseClinical Pharmacology Advances and Applications · 2013
  19. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjectsClinical Pharmacology Advances and Applications · 2013
  20. Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serumClinical Pharmacology Advances and Applications · 2013
  21. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetesClinical Pharmacology Advances and Applications · 2013
  22. High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failureClinical Pharmacology Advances and Applications · 2013
  23. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancerClinical Pharmacology Advances and Applications · 2013
  24. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137Clinical Pharmacology Advances and Applications · 2013
  25. Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic modelClinical Pharmacology Advances and Applications · 2013
  26. Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculationClinical Pharmacology Advances and Applications · 2013
  27. Use of ipilimumab in the treatment of melanomaClinical Pharmacology Advances and Applications · 2013
  28. Immunocytokines: a review of molecules in clinical development for cancer therapyClinical Pharmacology Advances and Applications · 2013
  29. Comparative safety and efficacy of antithrombotics in the management of venous thromboembolism after knee or hip replacement surgery: focus on rivaroxabanClinical Pharmacology Advances and Applications · 2013
  30. Single-dose fentanyl sublingual spray for breakthrough cancer painClinical Pharmacology Advances and Applications · 2013
  31. Impact of denosumab on bone mass in cancer patientsClinical Pharmacology Advances and Applications · 2013
  32. Synthetic cathinone abuseClinical Pharmacology Advances and Applications · 2013
  33. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III studyClinical Pharmacology Advances and Applications · 2013
  34. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorClinical Pharmacology Advances and Applications · 2013
  35. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaClinical Pharmacology Advances and Applications · 2013
  36. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorClinical Pharmacology Advances and Applications · 2013
  37. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown linesClinical Pharmacology Advances and Applications · 2013
  38. Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)Clinical Pharmacology Advances and Applications · 2013
  39. Arginine deprivation therapy for malignant melanomaClinical Pharmacology Advances and Applications · 2012
  40. Advances in the management of glioblastoma: the role of temozolomide and MGMT testingClinical Pharmacology Advances and Applications · 2012
  41. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical featuresClinical Pharmacology Advances and Applications · 2012
  42. Sedation in the intensive care settingClinical Pharmacology Advances and Applications · 2012
  43. Pazopanib for the treatment of soft-tissue sarcomaClinical Pharmacology Advances and Applications · 2012
  44. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamineClinical Pharmacology Advances and Applications · 2012
  45. Management of antipsychotic treatment discontinuation and interruptions using model-based simulationsClinical Pharmacology Advances and Applications · 2012
  46. Drug-resistant tuberculosis: emerging treatment optionsClinical Pharmacology Advances and Applications · 2011
  47. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case reportClinical Pharmacology Advances and Applications · 2011
  48. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisionsClinical Pharmacology Advances and Applications · 2011
  49. Detemir as a once-daily basal insulin in type 2 diabetesClinical Pharmacology Advances and Applications · 2011
  50. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndromeClinical Pharmacology Advances and Applications · 2011